Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q3 FY19 results · Oct–Dec 2018
Aarti Drugs reported revenue from operations of ₹380.10 crore and net profit of ₹20.89 crore for Q3 FY19 (Oct–Dec 2018), on a consolidated basis.
| Item | Q3 FY19 | Q3 FY18 | YoY | Q2 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 380.10 | — | — | 347.41 | +9.4% |
| Other income | 0.17 | — | — | 0.10 | +70.0% |
| Total income | 380.27 | — | — | 347.51 | +9.4% |
| Profit before tax | 30.83 | — | — | 26.73 | +15.3% |
| Net profit for the period | 20.89 | — | — | 18.05 | +15.7% |
| EPS, basic (₹) | 8.86 | — | — | 7.65 | +15.8% |
| Net margin (%) | 5.5 | — | 5.2 |
| Item | Q3 FY19 | Q3 FY18 | YoY | Q2 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 350.65 | — | — | 319.51 | +9.7% |
| Other income | 0.21 | — | — | 0.12 | +75.0% |
| Total income | 350.86 | — | — | 319.63 | +9.8% |
| Profit before tax | 31.05 | — | — | 26.68 | +16.4% |
| Net profit for the period | 21.15 | — | — | 18.03 | +17.3% |
| EPS, basic (₹) | 8.97 | — | — | 7.65 | +17.3% |
| Net margin (%) | 6.0 | — | 5.6 |
Consolidated
- Filed with BSE
- 12 Feb 2019, 11:31 IST
- Board meeting
- 11 Feb 2019
- Period
- 01 Oct 2018 to 31 Dec 2018
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Feb 2019, 11:31 IST
- Board meeting
- 11 Feb 2019
- Period
- 01 Oct 2018 to 31 Dec 2018
- Review status
- Audited
- Source
- XBRL filing on BSE